חוב לטווח קצר להון עצמי Titan Pharma (TTNP)

This chart of the current share price of Titan Pharmaceuticals (TTNP) reflects the dynamics of a company developing long-term drug delivery systems for addiction treatment. The business relies on strategic partnerships to implement the ProNeura platform, making the asset an attractive acquisition target. Meanwhile, the indicator stands at 0.00. The production cycle is supported via contract manufacturing sites featuring high-precision equipment calibration for implant assembly.

To select high-quality assets, it is essential for an investor to assess default risk via the ratio of short-term liabilities to equity, which measures the rate of debt accumulation relative to the resources of Titan Pharmaceuticals (TTNP). Given the company's revenue dependence on licensing payments, this short-term debt to equity chart on GURU.Markets clearly demonstrates the balance between financial stability and capital growth potential.